Please login to the form below

Not currently logged in
Email:
Password:

bipolar disorder

This page shows the latest bipolar disorder news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Italy in turmoil, Pharma attacks Europe's generics move and more

Daily Brief: Italy in turmoil, Pharma attacks Europe's generics move and more

Its pipeline includes Risperidone Extended-Release Microspheres for Injection candidate (LY03004) for schizophrenia and bipolar disorder, and plans to launch in China and the US by the end of 2018, while

Latest news

  • First digital medicine approved in the US First digital medicine approved in the US

    Abilify MyCite is the latest iteration of antipsychotic blockbuster Abilify (aripiprazole) to reach the market, and is approved for the same indications as its parent products - schizophrenia, bipolar I disorder and

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    Lundbeck and Otsuka start phase III for Rexulti in bipolar. Drug is also in phase II trial to treat PTSD patients. ... Otsuka and co-development partner Lundbeck have started two phase III trials of their atypical antipsychotic Rexulti in bipolar disorder

  • Lundbeck partners with 23andMe on first-of-its-kind study Lundbeck partners with 23andMe on first-of-its-kind study

    The US project will involve 25, 000 patients and combine data from genetics, cognitive tests and online surveys to explore how genetics is related to major depressive disorder (MDD), bipolar depression ... Anders Gersel Pedersen, executive VP, research

  • Otsuka refiles 'digital' medicine for mental illness Otsuka refiles 'digital' medicine for mental illness

    Abilify is approved to treat schizophrenia, bipolar disorder and major depressive disorder.

  • FDA knocks-back Otsuka's digital pill plans FDA knocks-back Otsuka's digital pill plans

    Otsuka had submitted the device for approval to measure medication adherence to Abilify (aripiprazole) in patients with schizophrenia, as an acute treatment of manic and mixed episodes associated with bipolar I ... disorder and as an adjunctive treatment

More from news
Approximately 7 fully matching, plus 85 partially matching documents found.

Latest Intelligence

  • Drug pricing in Ireland Drug pricing in Ireland

    As such, patients with coronary syndromes, multiple sclerosis, bipolar disorder and Hepatitis C were being denied access to effective treatments, while treatments for other diseases were also subject to restrictions.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics